Skip to content
Clinical Trials – home

Fakultna Nemocnica S Poliklinikou Zilina

Research site

Slovakia Vojtecha Spanyola 43, 010 01 Zilina, Slovakia

  • 7 trials recruiting
  • Neovascular age-related macular degeneration · Diabetic retinal oedema · Breast cancer
  • Adult patients

About Specializations

Fakultna Nemocnica S Poliklinikou Zilina in Zilina, Slovakia specialises in clinical trials of conditions such as Neovascular age-related macular degeneration, Diabetic retinal oedema, Breast cancer, Breast cancer metastatic, and other specialisations. This site conducts important research.

Main research areas of the site

Eye Diseases and Vision Research at Fakultna Nemocnica S Poliklinikou Zilina

Clinical trials in ophthalmology focus mainly on diabetic macular edema, neovascular age-related macular degeneration, and geographic atrophy. The research is aimed at comparing new eye therapies with established treatments and improving long-term visual outcomes for people with retinal disease.

  • Testing new and biosimilar treatments for diabetic macular edema and wet AMD
  • Evaluating treatment effectiveness for neovascular age-related macular degeneration
  • Studying options that may reduce injection burden while preserving vision

This work reflects a strong local focus on retinal disease care, with several studies comparing emerging therapies to widely used eye treatments.

Nervous System Diseases Research in Neurology

The site is also active in neurology, with studies centered on acute ischemic stroke, high-risk transient ischemic attack, and multiple sclerosis. These trials are designed to improve prevention, assess long-term safety, and support better management of serious neurological conditions.

  • Preventing recurrent events after stroke or transient ischemic attack
  • Monitoring long-term safety in multiple sclerosis
  • Supporting better treatment strategies for vascular and immune-related brain disease

The Neurology Department contributes to research that may help refine care for patients at risk of disability from cerebrovascular and chronic neurological disorders.

Neoplasms and Cancer Treatment Studies

Cancer-related trials at the hospital include breast cancer, prostate cancer, and non-small cell lung cancer. The main purpose is to evaluate new treatment options, compare them with current standards, and gather additional safety and effectiveness information for people with advanced disease.

  • Assessing new combinations for hormone receptor-positive, HER2-negative breast cancer
  • Collecting long-term data in prostate cancer
  • Comparing cancer therapies for advanced lung cancer

These studies show an interest in both targeted oncology and follow-up research that supports ongoing treatment decisions in advanced malignancies.

Bacterial Infections and Mycoses Studies

Research in this area includes trials for diabetic foot infections, where investigators are evaluating whether newer antibiotics can improve clinical response and safety compared with established therapy. The goal is to strengthen treatment options for infections that are often difficult to manage in patients with diabetes.

  • Testing new antibacterial treatment approaches for diabetic foot infections
  • Comparing clinical response and tolerability with standard care
  • Supporting better infection control in complex diabetic wounds

This infection-focused work adds an important anti-infective dimension to the site’s broader clinical trial portfolio.

Cardiovascular Diseases and Vascular Risk Research

Trials in cardiovascular medicine are centered on reducing the risk of ischemic stroke after a major warning event. The research is designed to test whether newer preventive therapies can lower future vascular complications compared with placebo or standard care.

  • Preventing recurrent stroke in high-risk patients
  • Evaluating therapies aimed at lowering thrombotic risk
  • Improving secondary prevention after cerebrovascular events

At Fakultna Nemocnica S Poliklinikou Zilina, this area connects closely with the hospital’s neurological expertise and its interest in vascular health.

Musculoskeletal Diseases and Related Care

The site’s trial activity also touches on musculoskeletal disease, mainly through studies linked to diabetic complications that affect mobility and daily function. The overall aim is to improve treatment effectiveness and support better recovery in patients with complex chronic illness.

  • Addressing complications that can affect movement and wound healing
  • Supporting better outcomes in diabetes-related conditions
  • Exploring therapies that may improve quality of life

Although smaller in scope, this research area adds to the site’s broad clinical focus across chronic disease management.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Vojtecha Spanyola 43010 01 ZilinaSlovakia
Recruiting now
7 trials
Conditions studied
12

More sites in ZilinaSlovakia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

18 clinical trials

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:BI 1815368
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Astellas Pharma Global Development Inc.

Study on the Safety and Effectiveness of Contezolid Acefosamil, Contezolid, and Linezolid for Adults with Moderate or Severe Diabetic Foot Infections

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Micurx Pharmaceuticals Inc.

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Diabetic retinal oedema+1

Not recruiting

Study on Aflibercept for Adults with Diabetic Macular Edema or Wet Age-Related Macular Degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Bayer AG

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Study Comparing RBS-001 and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Rophibio Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.